In the present study, a series of dibenzoazepine triazole derivatives (24-39)
were synthesized and evaluated for their in vitro bioactivities including antiglycation,
antibacterial, DPPH radical scavenging, urease inhibition, antileishmanial and immunomodulatory
activities. The compounds were found to be moderately active only
against leishmania. Within this series, compound 26 was found to be the most active
antileishaminals with IC50 value 37.4 ± 0.4 µM. Structure-activity relationships for
this novel class are discussed.
In vitro α-Glucosidase Inhibition by Non-sugar based Triazoles of Dibenzoazepine, their Structure-Activity Relationship, and Molecular Docking
作者:Maria A. Khan、Kulsoom Javaid、Abdul Wadood、Alam Jamal、Farhana Batool、Saba Fazal-ur-Rehman、Fatima Z. Basha、Muhammad I. Choudhary
DOI:10.2174/1573406413666170726142949
日期:2017.10.17
Background: α-Glucosidase inhibitors (AGIs) have been reported for their clinical potential
against postprandial hyperglycemia, which is responsible for the risks associated with diabetes mellitus
2 and cardiovascular diseases (CVDs). Besides, a number of compounds have been reported as potent
AGIs, several side effects are associated with them.
Methods: The aim of present work is to explore new and potent molecules as AGIs. Therefore, a library
of dibenzoazepine linked triazoles (1-15) was studied for their in vitro α-glucosidase inhibitory
activity. The binding modes of potent compounds in the active site of α-glucosidase enzyme were also
explored through molecular docking studies.
Results and Conclusion: Among the reported triazoles, compounds 3-9, 11, and 13 (IC50 = 6.0 ± 0.03
to 19.8 ± 0.28 µM) were found to be several fold more active than the standard drug acarbose (IC50 =
840 ± 1.73 µM). Compound 5 (IC50 = 6.0 ± 0.03 µM) was the most potent AGIs in the series, about 77-
fold more active than acarbose. Therefore, dibenzoazepine linked-triazoles described here can serve as
leads for further studies as new non-sugar AGIs.